Recent guidance from the United States Centers for Disease Control and Prevention that extended artemether–lumefantrine treatment for uncomplicated malaria from three days to five days does not justify changing national guidelines across African malaria programs, according to a perspective published in Discover Public Health. Authors Faith Adedayo Adejumo and Ayomide Raphael Ijabadeniyi explain that the updated regimen was developed specifically for clinical practice within the United States. Consequently, the authors emphasize that guidance tailored to American healthcare settings cannot independently determine therapeutic protocols across diverse African national contexts.
The perspective addresses rising concerns surrounding emerging resistance and reports of declining artemether–lumefantrine efficacy. Although artemisinin partial resistance and reduced treatment efficacy have been documented at selected African study sites, the authors clarify that these localized findings do not establish that the standard three-day regimen is ineffective across the entire continent. Because evidence of reduced efficacy remains confined to specific locations, broad generalizations regarding continental treatment failure remain unsupported by the available surveillance data.
Clinical trials conducted in Africa comparing three-day and five-day artemether–lumefantrine courses have confirmed that extended regimens achieve greater overall lumefantrine exposure in patients. However, Adejumo and Ijabadeniyi highlight that increased drug exposure alone fails to demonstrate superior clinical cure rates, reduced malaria recrudescence, or practical feasibility within routine healthcare delivery. Without direct evidence showing clear therapeutic improvements or programmatic viability, pharmacological exposure metrics cannot validate adopting longer treatment courses in public health programs.
Instead of blanket adoption across African countries, the authors advocate for geographically targeted evaluations of extended artemether–lumefantrine regimens to inform evidence-based policy decisions. They stress that future research must systematically integrate therapeutic efficacy outcomes with molecular resistance surveillance, detailed pharmacokinetic data, medicine-quality verification, and thorough assessments of patient adherence and real-world implementation. Ultimately, rigorous comparative studies must establish whether extended regimens provide meaningful clinical advantages over standard artemether–lumefantrine or alternative artemisinin-based combination therapies before national treatment policies are modified.
Subject of Research: Evaluation of extended artemether–lumefantrine regimens in African malaria programs
Article Title: Responding to declining artemether lumefantrine efficacy in African malaria programs
Article References: Adejumo, F. A., & Ijabadeniyi, A. R. (2026). Responding to declining artemether lumefantrine efficacy in African malaria programs. Discover Public Health, 23(1), Article 1818. https://doi.org/10.1186/s12982-026-03259-1
Image Credits: AI Generated
DOI: 10.1186/s12982-026-03259-1
Keywords: artemether-lumefantrine, malaria treatment, antimalarial drug resistance, African malaria programs, therapeutic efficacy, lumefantrine exposure, artemisinin partial resistance, pharmacokinetics, treatment adherence, molecular surveillance, uncomplicated malaria, medicine quality, public health policy, extended regimens, combination therapy, clinical trials
News Source: Ophelia Keating. (November 18, 2026). Five-Day Malaria Regimen Requires Targeted Evaluation Across African Programs. Scienmag.



